Drug Trial Radar · NCT03402152
NRX101 Glx Biomarker Validation Study
Last checked: Nov 19, 2026Latest source record: Aug 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Nov 1, 2018
Primary completion
Jan 1, 2021
Study completion Jun 1, 2021
Sponsor
- Lead sponsor
- NeuroRx, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Target Health Inc.
- First posted
- Jan 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD. Similarly, interventions that increase the level of Glx in the brain, specifically electroconvulsive therapy (ECT) and intravenous ketamine infusion have been associated with a rapid decrease in depression and suicidal ideation. This effect has been demonstrated in a dose-dependent manner in randomized clinical assessments. D-cycloserine, a glycine site modulator of NMDA receptor function has been demonstrated to increase Glx in the ACC of normal volunteers. The purpose of this study is to determine whether NRX-101, an experimental drug containing a fixed dose combination of D-cycloserine and lurasidone (1) raises Glx by a greater amount than either placebo or lurasidone alone in patients with bipolar depression, and (2) whether that elevation in Glx is correlated with a decrease in depression.
Conditions
- Bipolar Depression
- Suicidal Ideation
Interventions
NRX-101Drug
NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Lurasidone HClDrug
Lurasidone HCl will be given twice a day by mouth
PlaceboDrug
Placebo oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- GlxTime frame: Immediate
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New York State Psychiatric Institute
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.